The research team, led by Qianqian Yin and Yaru Yang of Xuzhou Central Hospital affiliated with Southeast University, together with colleagues including corresponding authors Xiaoyan Liu and Jianhua Zheng, recruited twenty patients diagnosed with PMOS and ten control women. Follicular fluid, the nutrient-rich liquid surrounding the oocyte inside each ovarian follicle, was collected during procedures related to in vitro fertilization and embryo transfer. Because this fluid is in direct contact with the developing egg and the surrounding cumulus cells, it offers a uniquely intimate window into the microenvironment in which fertilization competence is established. Rather than studying blood, where systemic changes can be diluted and confounded, the researchers chose to interrogate the immediate biochemical neighborhood of the egg itself.

The technological centerpiece of the study was four-dimensional label-free quantitative proteomics, an approach that has rapidly become one of the most powerful tools in modern biology. Traditional proteomic methods separate peptides along a single dimension of mass spectrometric analysis, but four-dimensional platforms add ion mobility separation and retention time alignment, dramatically increasing the depth, resolution, and accuracy of protein identification. Label-free quantification, meanwhile, avoids the chemical labeling steps that can introduce bias and expense, instead relying on the raw intensity of detected peptide signals to estimate relative protein abundance across samples. This combination allowed the team to comprehensively profile the whole proteome of follicular fluid and to detect subtle but meaningful differences between patient groups that earlier methods might have missed.

When the data were analyzed with strict statistical thresholds requiring a fold change greater than 1.5 and a p-value below 0.05, thirty-three proteins emerged as differentially expressed between the PMOS and control groups. Twenty-four of these proteins were elevated in the patients, while nine were reduced. That modest number may sound unremarkable, but each of these molecules represents a potential thread in the tangled web of PMOS pathogenesis, and the patterns revealed by subsequent bioinformatic analysis were strikingly coherent rather than random.

Functional enrichment analysis using the Gene Ontology framework showed that the altered proteins clustered around several biological themes. The first was immunoglobulin production and the humoral immune response, indicating that antibody-mediated immune activity is heightened within the follicular environment of PMOS patients. The second was leukocyte migration, suggesting that immune cells are being actively recruited into the ovarian follicle. The third and perhaps most surprising theme was cellular energy metabolism, with proteins involved in glycolysis and pyruvate metabolism prominently represented. These findings imply that the follicle in PMOS is not merely a passive site of hormonal dysfunction but an active immunometabolic battlefield where energy production and immune defense are simultaneously rewired.

Pathway-level analysis using the Kyoto Encyclopedia of Genes and Genomes reinforced this picture. The differentially expressed proteins were predominantly enriched in glycolysis and gluconeogenesis, pyruvate metabolism, the hypoxia-inducible factor-1 signaling pathway, and extracellular matrix-receptor interactions. The involvement of HIF-1 signaling is particularly intriguing. This pathway is the cell’s master response to low oxygen, and its activation can drive cells to shift their energy production from efficient mitochondrial respiration toward rapid but wasteful glycolysis, a phenomenon famously exploited by cancer cells. Its enrichment in PMOS follicular fluid raises the possibility that the ovarian follicle in these patients exists in a state of relative hypoxia or metabolic stress, forcing the egg and its supporting cells to operate under conditions that may compromise developmental potential.

Protein-protein interaction network analysis added another layer of insight, suggesting a synergistic relationship between metabolic reprogramming and immune dysregulation in PMOS. In other words, the altered energy metabolism and the disturbed immune signaling do not appear to be independent phenomena but are likely intertwined, each feeding into and amplifying the other. This kind of systems-level view is exactly what proteomics is designed to deliver, and it points toward a conceptual model in which PMOS arises from a self-reinforcing loop of inflammatory and metabolic disturbance within the ovary, rather than from a single defective gene or hormone.

To ensure that the mass spectrometry findings were not artifacts, the team turned to enzyme-linked immunosorbent assay, a targeted and highly specific method for measuring individual proteins. Three candidates were selected for validation: L-lactate dehydrogenase A chain, known as LDHA, a key enzyme that drives the final step of glycolysis and converts pyruvate into lactate; protein S100-A9, or S100A9, an inflammatory mediator released by neutrophils and monocytes that acts as a danger signal to the immune system; and serum amyloid A1, or SAA1, an acute-phase protein classically associated with inflammation and tissue remodeling. All three were confirmed to be significantly higher in the follicular fluid of PMOS patients than in controls, lending robust analytical credibility to the discovery set and highlighting a concrete biochemical axis linking glycolytic flux, inflammation, and acute-phase response within the follicle.

The implications of this work are twofold. Clinically, the identified proteins could serve as diagnostic biomarkers, offering a way to identify or monitor PMOS through a simple assessment of follicular fluid, and potentially as therapeutic targets whose modulation might restore a healthier follicular environment. Scientifically, the study reframes PMOS as a disorder of immunometabolic reprogramming and extracellular matrix remodeling, providing a new perspective on pathogenesis that goes beyond the traditional focus on androgen excess and insulin resistance. The authors are careful to note the limitations of their work: the sample size was modest, with twenty patients and ten controls, and the findings now require validation in larger cohorts, ideally integrated with detailed clinical phenotypes and functional experiments that can test whether the candidate proteins play causal roles or are merely markers of the disease process.

Nevertheless, the study stands as a compelling example of how cutting-edge proteomic technology can illuminate diseases that have long resisted conventional investigation. By capturing a snapshot of the protein milieu surrounding the human egg, Yin, Yang, and their colleagues have transformed PMOS from a vaguely defined clinical syndrome into a condition with a measurable molecular fingerprint. If subsequent research confirms and extends these findings, the glycolytic enzymes, inflammatory proteins, and matrix components identified in follicular fluid could become the foundation for new diagnostic tests and, ultimately, new treatments aimed at protecting the delicate metabolic environment in which every human life begins.

Subject of Research: Proteomic profiling of follicular fluid in polyendocrine metabolic ovarian syndrome

Article Title: Identification of differentially expressed proteins in follicular fluid from patients with polyendocrine metabolic ovarian syndrome using 4D label-free proteomics

Article References: Yin, Q., Yang, Y., Yan, X., Cao, Y., Liu, X., & Zheng, J. (2026). Identification of differentially expressed proteins in follicular fluid from patients with polyendocrine metabolic ovarian syndrome using 4D label-free proteomics. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02271-y

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02271-y

Keywords: polyendocrine metabolic ovarian syndrome, follicular fluid, proteomics, 4D label-free quantification, glycolysis, HIF-1 signaling, immune dysregulation, LDHA, S100A9, SAA1, biomarkers, fertility